Kilter Group’s Royalty Pharma RPRX Stock Holding History

Kilter Group’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.4K	Hold	50	–	–	﹤0.01%	887
2025 Q4	$1.93K	Hold	50	–	–	﹤0.01%	803
2025 Q3	$1.76K	Hold	50	–	–	﹤0.01%	700
2025 Q2	$1.8K	Buy	+50	New	+$1.66K	﹤0.01%	646

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Kilter Group's RPRX Position: Q1 2026 in Review

Kilter Group held its Royalty Pharma (RPRX) position steady in Q1 2026 at 50 shares worth $2.4K. The position accounts for ﹤0.01% of the portfolio, ranked #887.

Kilter Group first reported a position in RPRX in Q2 2025 and has held it in 4 quarters since. 587 funds tracked by Wall St. Rank hold RPRX as of Q1 2026.

Kilter Group held 50 shares of Royalty Pharma worth $2.4K as of Q1 2026.
Kilter Group left its Royalty Pharma share count unchanged in Q1 2026.
Royalty Pharma made up ﹤0.01% of Kilter Group's portfolio in Q1 2026, its #887 holding.
Kilter Group first reported a position in Royalty Pharma in Q2 2025 and has held it in 4 quarters since.
587 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2026.

Based on Kilter Group's 13F filing for Q1 2026, filed 14 May 2026.